Key Highlights

  • 22nd Century Group (NASDAQ:XXII) shows USD 0.07, up 6.47%, on 214.68 million shares (relative Volume 3.16) and a Market Value of USD 1.42 million on the penny stocks screen, as of the capture on November 4, 2026.
  • Hain Celestial (NASDAQ:HAIN) faces a Nasdaq deadline of March 22, 2027 to lift its shares back to USD 1.00.
  • Senti Biosciences (NASDAQ:SNTI) stockholders approved a Merger on October 15, 2026 that pays no cash at closing and offers contingent value rights of up to USD 60.0 million.
  • Context Therapeutics (NASDAQ:CNTX) reported cash of USD 43 million at June 30, 2026, which management says funds operations through the fourth quarter of 2027.

1. 22nd Century Group (NASDAQ:XXII)

22nd Century Group (NASDAQ:XXII) shareholders approved on August 5, 2026 a reverse split of up to 1-for-200 aimed at Nasdaq listing requirements. XXII is on this list because the penny stocks screen filters for very low share prices, where small orders can move a quote and spreads can be wide. They also authorised up to USD 30 million of financing: up to USD 20 million of convertible preferred stock with warrants and up to USD 10 million of common stock with warrants. They ratified 3,019,586 inducement warrants issued in June 2026. Published coverage reported an earlier 1-for-15 reverse split announced in January 2026, a single source item treated as approximate. This is a small and thinly traded name, so a few trades can move the quote, spreads can be wide and a gain can reverse.

2. Hain Celestial (NASDAQ:HAIN)

On the penny stocks screen, Hain Celestial (NASDAQ:HAIN) appears at USD 0.13, up 12.59%, on 2.72 million shares (relative volume 1.35) and a market value of USD 12.20 million, as of the capture on November 4, 2026. For HAIN, market value and volume matter more than price: a market value of a few million USD means a small number of trades can set the quote. Published coverage of the Annual Report put Debt of about USD 558 million due December 22, 2026 against about USD 58 million of cash, with Going Concern doubt; these figures are single source and approximate. The screen shows a loss per share of USD 3.36 and a Neutral rating. Hain Celestial said its shares closed below USD 1.00 for 30 consecutive Business days, and Nasdaq moved the listing to the Capital Market effective September 24, 2026, with compliance required by March 22, 2027. The risk is a going concern doubt with debt due on December 22, 2026, and a quote that can move sharply on small trades.

3. Senti Biosciences (NASDAQ:SNTI)

On the penny stocks screen, Senti Biosciences (NASDAQ:SNTI) appears at USD 0.19, up 13.87%, on 896,820 shares and a market value of USD 5.86 million, as of the capture on November 4, 2026. SNTI is on this list because the penny stocks screen filters for very low share prices, where small orders can move a quote and spreads can be wide. Stockholders also approved a reverse split between 1-for-20 and 1-for-50. Convertible notes mature on November 23, 2026 at 200% of principal and are expected to convert into about 46.8 million shares at USD 0.342. This is a small and thinly traded name, so a few trades can move the quote, spreads can be wide and a gain can reverse.

4. Acumen Pharmaceuticals (NASDAQ:ABOS)

On the penny stocks screen, Acumen Pharmaceuticals (NASDAQ:ABOS) appears at USD 0.24, up 14.09%, on 33.72 million shares (relative volume 4.42) and a market value of USD 17.34 million, as of the capture on November 4, 2026. A price below USD 1 is not a verdict on a business, but it can bring Listing Rules into play, such as the Nasdaq minimum bid price, and make financing dilutive for ABOS holders. Published coverage reported a one day fall of about 91% on October 30, a single source figure treated as approximate, which would make the latest rise a bounce from a very low base. The screen market value of USD 17.34 million is below the USD 78.6 million cash figure, simple arithmetic across a screen and a reported number. At this size a small number of trades can move the price, spreads can be wide and quoted moves can reverse, so a gain says nothing about what comes next.

5. Context Therapeutics (NASDAQ:CNTX)

On the penny stocks screen, Context Therapeutics (NASDAQ:CNTX) appears at USD 0.20, up 6.82%, on 1.29 million shares (relative volume 1.07) and a market value of USD 18.56 million, as of the capture on November 4, 2026. For CNTX, market value and volume matter more than price: a market value of a few million USD means a small number of trades can set the quote. Its lead candidate CTIM-76 received FDA Fast Track Designation in April 2026, and a Phase 1b expansion is expected to start in the first quarter of 2027. Published coverage reported a close of USD 0.69 on August 5, 2026, then a fall of 23.06% to USD 0.53 in overnight trading, single source figures treated as approximate. At this size a small number of trades can move the price, spreads can be wide and quoted moves can reverse, so a gain says nothing about what comes next.

Where Things Stand

Do not assume so. 22nd Century Group (NASDAQ:XXII) has authority for a reverse split of up to 1-for-200, HAIN faces a Nasdaq deadline of March 22, 2027, SNTI has convertible notes maturing on November 23, 2026, and ABOS is bouncing from a fall of about 91% reported by a single source, so each gain sits on a fragile base. Penny names are cheap per share but not necessarily cheap for the business: market values of a few million USD, going concern doubts and maturing notes appear across this screen, so the screen is a map of risk as much as of opportunity.